A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose and Dose Regimen-Ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-Positive Systemic Lupus Erythematosus Patients With Active Disease.

Trial Profile

A Phase IIb Randomized, Double-Blind, Placebo-Controlled, Dose and Dose Regimen-Ranging Study of the Safety and Efficacy of Epratuzumab in Serologically-Positive Systemic Lupus Erythematosus Patients With Active Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Epratuzumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms EMBLEM
  • Sponsors UCB
  • Most Recent Events

    • 04 Jun 2014 Results presented at the 19th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes.
    • 30 Oct 2013 Quality-of-life results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 09 Sep 2011 Additional location added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top